APRIL 23, SATURDAY

Biological examination in anti-ageing medicine 

9.30-10.00 Check-in

10.00-12.00
Conducting an anti-ageing consultation for men and women

Christophe de Jaeger (France), President of the European Institute on Ageing

12.00-12.30 Coffee break

12.30-14.30
Anti-ageing medicine – Swiss concept

Ronald Ballier, MD (Switzerland) the leading specialist and Medical Director for Preventive Medicine, SALUSMED Healthcare Centre (Switzerland)

• The concept of SALUSMED Healthcare Centre (Switzerland) and the Institute of Applied Biochemistry (IABC)
• Orthomolecular therapy

• The clinician’s and biochemist’s approach: biological and hormonal profile evaluation, individual treatment. A new vitamin formula.

• Clinical examples: diabetes, the metabolic syndrome, weight loss, the menopause, revitalization and rehabilitation.

14.30-15.30 Lunch

15.30-18.30
The detection and prevention of hereditary risks

Andrey Primak (Ukraine), Director of MEDICOM Anti-Ageing Clinic

• The role of genetic factors in the development of chronic disorders, significantly shortening life expectancy and impairing the quality of life:
  • The basic terminology of genetics
  • The criteria for the choice of genetic polymorphisms
• The gene polymorphism influencing the development of cardiovascular disorders:
  • Lipidic metabolism
  • Diagnosing dislipidemias
  • The polymorphism influencing lipidic metabolism
    • The APO E gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The CETP gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The SELE gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
  • The MTHFR gene:
    • The biochemistry of methylation processes
    • The physiological role of methylation processes
    • The diseases associated with methylation disorders
    • The gene’s polymorphism and its clinical significance
    • The therapeutic approach to the polymorphism
  • The polymorphism influencing the development of hypertension:
    • The GNB3 gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The AGT gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The AGTR1 gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
  • The polymorphism influencing blood coagulation processes
    • The coagulation factor II
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The factor V:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
  • The genetic polymorphism influencing detoxication processes
    • The fundamentals of detoxication processes
    • The pathological states associated with disorders of detoxication processes
    • Estrogen detoxication
    • Detoxication disorders diagnostics
    • The CYP1A1 gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The CYP1B1 gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The CYP3A4 gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The CYP2A6 gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The CYP2C9 gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The CYP2D6 gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The CYP2E1 gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The GSTM1 gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The GSTP1 gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The NAT1 and NAT2 genes:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The COMT gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
  • The genetic polymorphism influencing antioxidant defense
    • The fundamentals of antioxidant defense
    • The causes of oxidation stress
    • Oxidation stress diagnostics
  • The SOD1 gene:
    • The gene’s polymorphism and its clinical significance
    • The therapeutic approach to the polymorphism
  • The SOD2 gene:
    • The gene’s polymorphism and its clinical significance
    • The therapeutic approach to the polymorphism
  • The polymorphism of the genes encoding various immune system mediators:
    • An overview of cytokines
    • The IL-1b gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The IL-1RN gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The TNF-a gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The IL-4 gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The IL-6 gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The IL-10 gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The IL-13 gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
  • The polymorphism of the genes encoding the formation of connective tissue
    • The CALCR gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The VDR gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The IL-1RN gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism
    • The TNF-a gene:
      • The gene’s polymorphism and its clinical significance
      • The therapeutic approach to the polymorphism

18.30-19.00 Round-table discussion

APRIL 24, SUNDAY

10.00-18.00
The eight modifiable risk factors for pathological ageing: their functional laboratory assessment and integrative treatment methods

Michael Calp (Great Britain), МА, ND, Integrative Health Solutions, LTD

• Chronic inflammation
• Deterioration of gastrointestinal tract function
• Insulin resistance
• Mitochondrial function disorder
• Detoxication disorder
• Methylation deficiency
• Immunodeficiency
• Hormone balance disorder

The goals and objectives of the presentation:

• A comprehensive view of the clinical aspects of pathological ageing
• The fundamentals of its genetic foundations
• The role of nutrition and lifestyle as well as endocrine and immunologic status in the aetiology and pathogenesis of ageing-related diseases
• Clinical diagnostic tests for early recognition of a variety of interrelated physiological functional disorders aggravating chronic diseases associated with ageing
• Some effective therapeutic regimens contributing to the relief of physiological disorders and improving the state of health

12.00-12.30 Coffee break

14.00-15.00 Lunch

APRIL 25, MONDAY

10.00-18.00
Ageing in women: hormonal disorders and their symptoms, the modern views of hormone replacement therapy, alternative treatment methods

Prof. Vera Smetnik (Russia), MD, Honoured Scientist of Russian Federation, President of the Russian Gynaecologists/Endocrinologists Association and the Russian Menopause Association, Director of the Gynaecological Endocrinology Department of the Research Centre for Obstetrics, Gynaecology and Perinatology of the Russian Academy of Medical Sciences

Vera Balan (Russia), MD, Senior Staff Scientist of the Research Centre for Obstetrics, Gynaecology and Perinatology of the Russian Academy of Medical Sciences

• The physiology of the menopause, a classification of menopausal disorders
• The climacteric syndrome: methods of treatment
• Urogenital disorders
• Osteoporosis
• Hormone replacement therapy: principles, regimens, indications and contra-indications, treatment efficiency assessment

12.00-12.30 Coffee break

14.00-15.00 Lunch

18.00-18.30 Round-table discussion

28.02.2005

Print version